Triodos Investment Management BV Acquires 8,500 Shares of Hologic, Inc. $HOLX

Key Points

• Triodos Investment Management BV has increased its stake in Hologic, Inc. by 16.2%, now holding 61,000 shares valued at approximately $3.97 million.
• Analyst ratings for Hologic are generally positive, with a consensus target price of $80.15 and various firms issuing price objectives between $75.00 and $87.00.
• Hologic reported earnings of $1.08 per share for the latest quarter, exceeding analyst expectations, and has set guidance for future earnings between 1.090-1.120 EPS for Q4 2025.

Triodos Investment Management BV boosted its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 16.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 61,000 shares of the medical equipment provider's stock after purchasing an additional 8,500 shares during the period. Triodos Investment Management BV's holdings in Hologic were worth $3,974,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its stake in Hologic by 22.3% in the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after purchasing an additional 335 shares during the last quarter. United Services Automobile Association bought a new stake in Hologic in the first quarter worth $347,000. SG Americas Securities LLC lifted its stake in Hologic by 116.6% in the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock worth $594,000 after purchasing an additional 5,172 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Hologic in the first quarter worth $641,000. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in Hologic by 1.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock worth $1,980,000 after purchasing an additional 528 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

HOLX has been the topic of a number of analyst reports. Stephens restated an "overweight" rating and issued a $78.00 price objective on shares of Hologic in a research report on Thursday, September 18th. Mizuho set a $75.00 price objective on shares of Hologic in a research report on Thursday, July 31st. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and boosted their price objective for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Evercore ISI set a $78.00 price objective on shares of Hologic and gave the company an "outperform" rating in a research report on Tuesday. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Hologic in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $80.15.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $68.62 on Friday. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The company's 50-day moving average is $67.14 and its 200 day moving average is $63.26. The stock has a market capitalization of $15.26 billion, a P/E ratio of 28.47, a P/E/G ratio of 2.34 and a beta of 0.63.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter in the previous year, the company earned $1.06 earnings per share. Hologic's quarterly revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insiders Place Their Bets

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the company's stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.88% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.